Daejin Abidoye

Daejin Abidoye, M.D., is the Vice President and therapeutic area head for solid tumor oncology at AbbVie. In this engaging conversation, he delves into the transformative potential of antibody-drug conjugates (ADCs) in cancer care. He discusses AbbVie's breakthrough approval of Emrelis for lung cancer, the promising future of ADCs beyond chemotherapy, and exciting advancements from the recent ASCO conference. Abidoye also highlights innovative compounds targeting various cancers and the growing importance of precision medicine in oncology.